An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...
The company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.
Zacks Small Cap Research on MSN3d
HURA: Initiating an Immune ResponseHURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...
StudyFinds on MSN1d
Personalized vaccines halt kidney cancer after encouraging phase 1 trialGroundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...
In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.
HealthDay on MSN1d
Experimental vaccine seems to battle advanced kidney cancersA small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...
Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...
Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a ...
A cancer vaccine generated using the cells left over after tumour removal surgery could help to keep patients from ...
Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback